Speciality chemicals group Elementis continues to buy back shares and has confirmed a new senior independent director, following first-half results that showed rising margins and lower debt.

Elementis (LSE:ELM), the FTSE 250 speciality chemicals company focused on additives for personal care products and coatings, has been steadily working through its share buyback programme in recent weeks, with the latest weekly disclosure published on 5 October. The company has also formalised its board leadership, confirming on 16 September that Christine Soden has been appointed senior independent director with immediate effect. Ms Soden, who chairs the audit committee, had held the role on an interim basis since March. An independent non-executive director since November 2020, she also sits on the remuneration and nomination committees and is the designated director for employee engagement.

While these updates are routine, they come against the backdrop of a first half in which Elementis delivered firmer margins, higher Earnings and a reduction in net debt, giving it the flexibility to return Capital to shareholders. The company produces specialist additives, including hectorite clay-based rheology modifiers and talc, which help control the texture and performance of products ranging from cosmetics and antiperspirants to paints and industrial coatings.

First-half results recap

For the six months to 30 June, Elementis reported Revenue of $318.2m, up 9.4% on a reported basis and 4.7% organically. Adjusted operating profit rose 16.4% to $73.2m, and the adjusted operating Margin improved to 23.0% from 21.6% a year earlier. Adjusted Diluted Earnings per Share climbed nearly 29% to 8.5 cents, Statutory operating profit rose 18.6% to $65.7m, and the Interim Dividend was increased by about 15% to 1.5 cents, paid in late September.

Both divisions contributed. Personal Care revenue rose 10% to $109.2m, with an adjusted Operating Margin of 38.1%, which included a benefit from the sale of its pharmaceutical business. Coatings revenue increased 9.1% to $209.0m, and adjusted operating profit in the division rose almost 24%, lifting its margin to 20.7%.

Balance sheet and capital returns

Net Debt fell to $163.8m at the end of June from $185.4m at the end of 2025, leaving Leverage at about 1.1 times EBITDA. That strengthened position allowed Elementis to launch a new share buyback of around £25m, funded by proceeds from the pharmaceutical disposal. By the end of the half, the company had spent about $4.1m buying back 2.0 million shares, and regular weekly updates since then show the programme continuing.

The group also recorded a small gain from a refund of US customs duties following a Supreme Court ruling earlier in the year on certain tariffs, which was treated as an adjusting item.

Outlook and what to watch

Elementis said it was confident of delivering full-year performance in line with market expectations, while monitoring risks linked to the conflict in the Middle East, which has affected energy and raw material costs across the chemicals sector. Company-compiled consensus at the time pointed to full-year adjusted operating profit of around $132.5m.

Looking ahead, investors will watch for evidence that organic Volume growth can be sustained in a mixed industrial environment, particularly in coatings markets tied to construction and industrial activity. Pricing discipline, raw material costs and the pace of buyback execution will also be important. The group's ability to keep expanding margins towards its medium-term targets will be key to how it is valued relative to other chemicals and industrials companies in the FTSE 250.